Dermira to Present at Upcoming Investor Conferences in November
November 09 2017 - 5:36PM
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced that company
management will present an overview of the company at two investor
conferences in November.
- Stifel 2017 Healthcare Conference
- Location: New York, NY
- Presentation date: Wednesday, November 15, 2017
- Presentation time: 2:45 p.m. ET
- Evercore ISI Biopharma Catalyst/Deep Dive Conference
- Location: Boston Harbor Hotel, Boston, MA
- Presentation date: Thursday, November 30, 2017
- Presentation time: 8:45 a.m. ET
A live audio webcast and archive of the presentations will be
available at http://investor.dermira.com.
About DermiraDermira is a
biopharmaceutical company dedicated to bringing biotech ingenuity
to medical dermatology by delivering differentiated, new therapies
to the millions of patients living with chronic skin
conditions. Dermira is committed to understanding the
needs of both patients and physicians and using its insight to
identify and develop leading-edge medical dermatology programs.
Dermira’s pipeline includes three late-stage product candidates
that could have a profound impact on the lives of patients:
glycopyrronium tosylate (formerly DRM04), for which a New Drug
Application is under review by the U.S. Food and Drug
Administration for the treatment of primary axillary hyperhidrosis
(excessive underarm sweating beyond what is needed for normal body
temperature regulation); olumacostat glasaretil (formerly DRM01),
in Phase 3 development for the treatment of acne vulgaris; and
lebrikizumab, for which Dermira plans to initiate a Phase 2b
dose-ranging study for the treatment of moderate-to-severe atopic
dermatitis. Dermira is headquartered in Menlo Park,
Calif. For more information, please
visit http://www.dermira.com. Follow @DermiraInc on Twitter
and LinkedIn.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc) and
corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Dermira may use these
channels to comply with its disclosure obligations under Regulation
FD. Therefore, investors should monitor Dermira’s website, LinkedIn
page and Twitter account in addition to following
its SEC filings, press releases, public conference calls
and webcasts.
Forward-Looking Statements The information in
this press release contains forward-looking statements and
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which are subject to the “safe harbor” created
by those sections. This press release contains forward-looking
statements that involve substantial risks and uncertainties,
including statements with respect to: Dermira’s goal of building a
leading medical dermatology company dedicated to delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions; Dermira’s plan to develop and
commercialize lebrikizumab for moderate-to-severe atopic
dermatitis; and Dermira’s plan to initiate a Phase 2b dose-ranging
study of lebrikizumab for moderate-to-severe atopic dermatitis.
These statements deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to the design, implementation and outcomes of Dermira’s
clinical trials; Dermira’s dependence on third-party clinical
research organizations, manufacturers and suppliers; the outcomes
of future meetings with regulatory agencies; and Dermira’s ability
to continue to stay in compliance with applicable laws and
regulations. You should refer to the section entitled “Risk
Factors” set forth in Dermira’s Annual Report on Form 10-K,
Dermira’s Quarterly Reports on Form 10-Q and other
filings Dermira makes with the SEC from time to
time for a discussion of important factors that may cause actual
results to differ materially from those expressed or implied by
Dermira’s forward-looking statements. Furthermore, such
forward-looking statements speak only as of the date of this press
release. Dermira undertakes no obligation to publicly
update any forward-looking statements or reasons why actual results
might differ, whether as a result of new information, future events
or otherwise, except as required by law.
Contacts:
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216erica.jefferson@dermira.com
Investors:Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
Robert H. Uhl Westwicke PartnersManaging
Director858-356-5932Robert.uhl@westwicke.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Sep 2023 to Sep 2024